The purpose of this study is to define the dose-limiting toxicities and maximum tolerated dose of the poly ADP-ribose polymerase inhibitor niraparib and escalating doses of temozolomide and/or irinotecan in patients with pre-treated incurable Ewing sarcoma.
|Treatment||Temozolomide, Irinotecan, Niraparib|
|Clinical Study Identifier||NCT02044120|
|Sponsor||Sarcoma Alliance for Research through Collaboration|
|Last Modified on||17 January 2021|
Select a piece of text and start making personal notes.
Congrats! You have your own personal workspace now.